INTROGEN THERAPEUTICS –

Austin, Texas

Went public 10/12/00 at $8 per share

Filing Range:5.0 million shares @ $8 to $10

Shares Outstanding:20.46 million shares

Underwriters: SG Cowen Securities/PaineWebber/Prudential Vector Healthcare

Company Counsel: Wilson Sonsini Goodrich & Rosati

Manager Counsel: Shearman & Sterling

Auditor: Arthur Andersen & Co.

The Company:

Develops gene therapy products for the treatment of cancer. Introgen

Therapeutics’ drug discovery and development programs have resulted in innovative approaches in which physicians use genes to treat cancer by directly addressing the genetic abnormalities associated with the disease.

Venture Backers:

Rhone Poulenc

Nomura Overseas Enterprises

Financing Rounds:

Number of Round Amt.

Round # Round Date Stage Investors ($ thousands)

1 08/01/1994 1 Early Stage 527.0

2 03/01/1996 2 Early Stage 14496.0

3 06/01/1996 2 Expansion 4770.0

4 10/01/1997 2 Expansion 11000.0

Financials:

(Data in $ millions)

Y/E

06/30/00

Total Revenues: $8.4

Net Income: -7.7